Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401 Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Drug Resistance, Neoplasm
  • Prostatic Neoplasms

abstract

  • Despite an improvement in PFS and OR, the addition of bevacizumab to docetaxel and prednisone did not improve OS in men with mCRPC and was associated with greater toxicity.

publication date

  • May 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3383121

Digital Object Identifier (DOI)

  • 10.1200/JCO.2011.39.4767

PubMed ID

  • 22454414

Additional Document Info

start page

  • 1534

end page

  • 40

volume

  • 30

number

  • 13